Argos Therapeutics, Inc. Stock

ARGSQ

US0402212023

Pharmaceuticals

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-6.22%	+78.50%

24/09/19	Argos Therapeutics, Inc. Went Out of Business	CI
24/09/19	First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.	CI

Valuation : Argos Therapeutics, Inc.

Market Cap	318K 274K 258K 235K 440K 30M 443K 3.06M 1.19M 15.34M 1.19M 1.17M 50.39M	P/E 2016	-2.96x	P/E 2017	-0.22x
Enterprise Value	4.58M 3.96M 3.73M 3.39M 6.35M 433M 6.39M 44.11M 17.12M 221M 17.22M 16.84M 727M	EV / Sales 2016	200x	EV / Sales 2017	9.19x
Free-Float	88.73%	Yield 2016 *	-	Yield 2017	-

* Estimated data More valuation ratios

Latest news : Argos Therapeutics, Inc.

24/09/19	Argos Therapeutics, Inc. Went Out of Business	CI
24/09/19	First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.	CI
30/08/19	First Amended Liquidation Plan Filed by Argos Therapeutics, Inc.	CI
21/03/19	Revised Disclosure Statement Approved on Interim Basis for Argos Therapeutics, Inc.	CI
15/03/19	Liquidation Plan and Disclosure Statement Filed by Argos Therapeutics, Inc.	CI
13/02/19	Genexine Inc. and SCM Lifescience Co. completed the acquisition of substantially all of the assets of Argos Therapeutics Inc.	CI
23/01/19	Motion for Asset Sale Approved for Argos Therapeutics, Inc.	CI
22/01/19	Notice of Successful Bidder Filed by Argos Therapeutics, Inc.	CI
22/01/19	Genexine Inc. and SCM Lifescience Co. entered into an asset purchase agreement to acquire substantially all of the assets of Argos Therapeutics Inc. for $11.3 million.	CI
22/01/19	CELLSCRIPT, LLC and Immune and Cell Therapies, LLC cancelled the acquisition of substantially all of the non-cash assets of Argos Therapeutics, Inc..	CI
20/12/18	Bidding Procedure Approved for Argos Therapeutics, Inc.	CI
06/12/18	Argos Therapeutics, Inc. will Change its Ticker to ARGSQ from ARGS	CI
04/12/18	Argos Therapeutics, Inc. Announces Management Changes	CI

More news

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Employees

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
ARGSQ Stock

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGOS THERAPEUTICS, INC.	-.--%	-6.22%	-	-	567K
REGENERON PHARMACEUTICALS, INC.	-0.83%	+4.77%	+50.09%	+2.83%	85.08B
MODERNA, INC.	-2.81%	+2.70%	+509.69%	+34.08%	60.21B
CSL LIMITED	+0.95%	+0.93%	-15.06%	-34.62%	59.71B
SAMSUNG BIOLOGICS CO.,LTD.	-1.25%	-6.13%	-2.08%	+33.18%	51.1B
UCB	+0.05%	-0.59%	+9.21%	+169.95%	48.73B
BIOGEN INC.	-0.15%	+0.64%	+57.41%	-16.29%	32.9B
INCYTE CORPORATION	-1.02%	-0.41%	+46.29%	+101.03%	26.11B
INNOVENT BIOLOGICS, INC.	+0.79%	-4.65%	-4.11%	+197.39%	22.6B
SWEDISH ORPHAN BIOVITRUM AB	+1.12%	-2.01%	+63.60%	+112.42%	16.42B
Average	-0.32%	-2.40%	+79.45%	+66.66%	40.29B
Weighted average by Cap.	-0.60%	-1.44%	+95.42%	+46.20%

	2016	2017
Net sales	945K 816K 768K 700K 1.31M 89.31M 1.32M 9.1M 3.53M 45.66M 3.55M 3.47M 150M	1.9M 1.64M 1.54M 1.41M 2.63M 179M 2.65M 18.27M 7.09M 91.74M 7.13M 6.98M 301M
Net income	-53.03M -45.75M -43.09M -39.26M -73.39M -5.01B -73.94M -510M -198M -2.56B -199M -195M -8.41B	-40.58M -35.01M -32.98M -30.05M -56.16M -3.83B -56.58M -390M -152M -1.96B -152M -149M -6.44B
Net Debt	-13.11M -11.31M -10.65M -9.71M -18.14M -1.24B -18.28M -126M -48.95M -633M -49.22M -48.15M -2.08B	4.27M 3.68M 3.47M 3.16M 5.91M 403M 5.95M 41.06M 15.93M 206M 16.02M 15.67M 677M

Argos Therapeutics, Inc. Stock

Stocks

ARGSQ

US0402212023

Pharmaceuticals

Valuation : Argos Therapeutics, Inc.

Latest news : Argos Therapeutics, Inc.

Biopharmaceuticals

Financials

Company Profile